PMID- 35620334
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2228-5881 (Print)
IS  - 2251-7308 (Electronic)
IS  - 2228-5881 (Linking)
VI  - 12
IP  - 2
DP  - 2022 Mar
TI  - Exendin-4 as a Versatile Therapeutic Agent for the Amelioration of Diabetic 
      Changes.
PG  - 237-247
LID - 10.34172/apb.2022.025 [doi]
AB  - Type 2 diabetes mellitus (T2DM) is a chronic metabolic abnormality leading to 
      microvascular and macrovascular complications. Non-insulin Incretin mimic 
      synthetic peptide exendin-4 was introduced as an anti-diabetic drug which helped 
      diabetic patients with triggering insulin secretion; further researches have 
      revealed an effective role of exendin-4 in treatment of T2DM related diseases. 
      Exendin-4 is approximately similar to Glucagon-like peptide, thus it can bind to 
      the glucagon-like peptide-1 receptor (GLP-1R) and activated different signaling 
      pathways that are involved in various bioactivities such as apoptosis, insulin 
      secretion and inactivation of microglial. In this review, we investigated the 
      interesting role of exendin-4 in various kinds of T2DM related disorders through 
      the activation of different signaling pathways.
CI  - (c)2022 The Authors.
FAU - Rajabi, Hadi
AU  - Rajabi H
AUID- ORCID: 0000-0001-6086-591X
AD  - Koc University Research Center for Translational Medicine (KUTTAM), Koc 
      University School of Medicine, Istanbul, Turkey.
FAU - Ahmadi, Mahdi
AU  - Ahmadi M
AD  - Tuberculosis and Lung Diseases Research Center, Tabriz University of Medical 
      Sciences, Tabriz, Iran.
FAU - Aslani, Somayeh
AU  - Aslani S
AD  - Department of Biochemistry and Clinical Laboratories, Faculty of Medicine, Tabriz 
      University of Medical Sciences, Tabriz, Iran.
FAU - Saberianpour, Shirin
AU  - Saberianpour S
AD  - Vascular and Endovascular Surgery Research Center, Mashhad University of Medical 
      Sciences, Mashhad, Iran.
FAU - Rahbarghazi, Reza
AU  - Rahbarghazi R
AUID- ORCID: 0000-0003-3864-9166
AD  - Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
AD  - Department of Applied Cell Sciences, Faculty of Advanced Medical Sciences, Tabriz 
      University of Medical Sciences, Tabriz, Iran.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210131
PL  - Iran
TA  - Adv Pharm Bull
JT  - Advanced pharmaceutical bulletin
JID - 101578021
PMC - PMC9106955
OTO - NOTNLM
OT  - Diabetes complications
OT  - Exendin-4
OT  - Signaling pathways
EDAT- 2022/05/28 06:00
MHDA- 2022/05/28 06:01
PMCR- 2021/01/31
CRDT- 2022/05/27 02:27
PHST- 2020/06/02 00:00 [received]
PHST- 2020/10/31 00:00 [revised]
PHST- 2021/01/29 00:00 [accepted]
PHST- 2022/05/27 02:27 [entrez]
PHST- 2022/05/28 06:00 [pubmed]
PHST- 2022/05/28 06:01 [medline]
PHST- 2021/01/31 00:00 [pmc-release]
AID - 10.34172/apb.2022.025 [doi]
PST - ppublish
SO  - Adv Pharm Bull. 2022 Mar;12(2):237-247. doi: 10.34172/apb.2022.025. Epub 2021 Jan 
      31.